Since the discovery that the HIF-1 pathway regulates the activation of many proangiogenic factors in tumours and may promote metastasis, the HIF-1α subunit has been considered an attractive target for new cancer therapeutics. The gene discussed is HIF1A; the disease is neoplasm.